YJYuxia Jiang

Yuxia Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuxia Jiang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Zheng

    Tongde Hospital of Zhejiang Province Afflicted to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province) Hangzhou Zhejiang China

    1 shared publication
  • Chuanwei Xin

    Tongde Hospital of Zhejiang Province Afflicted to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province) Hangzhou Zhejiang China

    1 shared publication
  • Chuanyong Su

    Department of Hematology, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Tongde Hospital of Zhejiang Province , Hangzhou, Zhejiang 310012

    1 shared publication
  • Haiying Wu

    Tongde Hospital of Zhejiang Province Afflicted to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province) Hangzhou Zhejiang China

    1 shared publication
  • Huifang Jiang

    Department of Hematology Tongde Hospital of Zhejiang Province Hangzhou China

    1 shared publication
  • Jia-Qi He

    The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China

    1 shared publication

Latest Publications

  • Open Access

    Betulin Protects Against Cardiac Hypertrophy by Improving AMPK /Nrf2‐Dependent Mitochondrial Function

    by Bei Zheng, Mingyang He, Haiying Wu, Tianjie Zhang, Yuxia Jiang, Chuanwei Xin, Meiling Zhang, Jiaqi He, Lulu Zheng

    Pathological cardiac hypertrophy (PCH) drives heart failure and affects global mortality, without specific pharmacotherapy. Betulin is a natural pentacyclic triterpene exhibiting diverse pharmacological properties. We investigated the therapeutic potential and underlying mechanisms of betulin in PCH. PCH was induced in C57BL/6J mice via angiotensin II (Ang II) infusion and transverse aortic constriction, with betulin administered in the last 2 weeks. Cardiac function was evaluated using echocardiography, and myocardial injury and remodeling were assessed using histological staining and molecular analyses. RNA sequencing and biochemical analyses elucidated molecular mechanisms. Molecular docking (MD) and molecular dynamics simulations (MDS) analyses predicted potential binding modes of betulin with AMP‐activated protein kinase (AMPK) and nuclear factor erythroid 2‐related factor 2 (Nrf2). To confirm AMPK/Nrf2 pathway‐dependent mitoprotective and cardioprotective effects of betulin, the AMPKα2 −/− mice, AMPK inhibitor, siNrf2, and AMPK agonist intervention were used. Betulin treatment significantly ameliorated cardiac hypertrophy, fibrosis (reducing fibrotic area by 65%), and dysfunction (increasing EF by 13.8% and FS by 11.6%) in PCH mice. Transcriptomic and biochemical analyses revealed that betulin activated AMPK phosphorylation, promoted Nrf2 nuclear translocation, and upregulated antioxidant genes, restoring mitochondrial function in hypertrophied hearts and Ang II‐stimulated cardiomyocytes. MD and MDS analyses indicated that betulin enhanced interactions between AMPK and Nrf2. AMPK inhibition significantly reversed betulin‐mediated alleviation of mitochondrial dysfunction by the AMPK/Nrf2 signaling axis. Cardioprotective effects of betulin were abolished in AMPKα2 −/− mice and Nrf2‐deficient cardiomyocytes. Betulin ameliorates pressure overload‐induced PCH and mitochondrial dysfunction by activating AMPK/Nrf2 signaling pathway, highlighting it as a therapeutic agent for PCH.


  • Immunophenotypic Characterization of Neoplastic T Follicular Helper Cells by Flow Cytometry

    by Xin Jin, Zhilu Chen, Qing Pan, Shuyuan Tian, Yuxia Jiang, Chuanyong Su, Wenfei Zhou, Huifang Jiang

    Background: T follicular helper (TFH) cell lymphoma is complex, and we hope to provide a new perspective for its diagnosis. Methods: We analysed the immunophenotypes of 89 mature T‐cell lymphomas, including 52 nodal lymphomas of TFH origin, as well as 32 benign lymph node samples and 30 healthy bone marrow samples, by flow cytometry (FCM). Results: Among pan‐T cell markers, CD4 + CD5 + CD3 − is the typical pattern that distinguishes TFH lymphoma from other T‐cell lymphomas. Specific markers with high sensitivity for the diagnosis of TFH lymphoma include programmed cell death protein 1 (PD‐1) and inducible synergistic co‐stimulation molecules (ICOS), which are expressed at lower levels in neoplastic TFH cells than in benign TFH cells. In contrast, the specificity of C‐X‐C chemokine receptor type 5 (CXCR5) and CD10 is high, and the proportion of CD10‐positive cells in neoplastic TFH samples is greater than that in benign TFH samples. Of the 52 TFH lymphoma samples in our study, 7 presented with abnormalities in B cells or plasmablast cells; we considered these to indicate B‐cell proliferation rather than composite lymphoma. Conclusion: Immunophenotypic characterization of neoplastic TFH cells by FCM is unique and has diagnostic value. Each specimen of suspected TFH lymphoma should be analyzed for the presence of specific markers, such as PD‐1, ICOS, CXCR5, and CD10, and the clonality of B cells and plasmablast cells should be assessed.